Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir PK in Healthy Volunteers
NCT02478463Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoint: Cabotegravir Concentration in Plasma and Tissues at Week 52. Started Feb 2017; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02478463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478463.